nad plus
Regeneration vs degeneration — where this fits
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why it would work (logic chain)
No mechanism chain catalogued yet.
How many people take it
There is no reliable global count of how many people take this compound. That number is not in this ledger.
What we can count from this ledger:
- 0 anecdote source(s) (posts, threads, comments)
- 0 anecdote-tier claim(s) derived from them
Logic: Without catalogued Reddit/X posts, this article cannot answer how many people take it — only what studies exist.
Evidence inventory
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 12
- Claims tagged human evidence: 0
- Claims tagged preclinical (animal/lab): 0
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 12
Logic: Studies exist in the ledger, but none are graded as strong human proof for the uses people discuss online. Animal and lab work is not the same as proof in people.
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.25 / 1.00 — low — animal and anecdote heavy
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review (source s1)
2024 systematic review of RCTs on NAD+/NADH supplementation safety and efficacy across conditions like CFS, Parkinson's, Alzheimer's; concludes well-tolerated with some benefits in quality of life and parameters, low side effects.
Evidence type: Published research.
NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence (source s2)
2026 PRISMA systematic review of 113 studies (up to Oct 2025) on NAD+ precursors; strong preclinical effects, human trials show NAD boosting and tolerability but heterogeneous/inconclusive functional outcomes; calls for larger trials.
Evidence type: Published research.
Effects of NAD+ supplementation with oral nicotinamide riboside on vascular health and cognitive function in older adults with peripheral artery disease: Results from a pilot 4-week open-label clinical trial (source s3)
2025 pilot open-label trial (NCT06534944) of NR in 8 older PAD patients; showed trends/improvements in endothelial function, cerebrovascular responses, cognition, and in vitro endothelial benefits via reduced oxidative stress.
Evidence type: Published research.
Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial (source s4)
2026 RCT showing IV NAD+ improves LVEF and trends toward better outcomes in heart failure patients.
Evidence type: Published research.
The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans (source s5)
2026 RCT comparing NR, NMN, and Nam effects on NAD levels and gut microbiota.
Evidence type: Published research.
NAD+ precursor supplementation in human ageing: clinical evidence and challenges (source s6)
Recent review on clinical evidence for NAD+ precursors in aging.
Evidence type: Published research.
Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting (source s7)
2026 pilot study comparing IV NAD+ and NR tolerability.
Evidence type: Published research.
Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials (source s8)
Systematic review and meta-analysis of RCTs on oral NMN for glucose and lipid metabolism in adults; shows NAD elevation but heterogeneous clinical outcomes.
Evidence type: Published research.
Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment (source s9)
Double-blind RCT showing 8 weeks NR safe, lowers AD biomarker pTau217, no cognitive change in older adults with SCD/MCI.
Evidence type: Published research.
Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial (source s10)
Pilot RCT of NR plus aerobic exercise for hypertension in middle-aged/older adults; tests efficacy for BP control.
Evidence type: Published research.
NAD+ and Niacin Supplementation as Possible Treatments for Glaucoma and Age-Related Macular Degeneration: A Narrative Review (source s11)
Narrative review on NAD+ and niacin for glaucoma and AMD management based on preclinical/clinical evidence.
Evidence type: Published research.
Role of nicotinamide adenine dinucleotide in cardiovascular diseases and therapeutics (source s12)
Review on NAD+ role in cardiovascular diseases and potential therapeutics.
Evidence type: Published research.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Ask this article · 2 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.